Feasibility and Safety of Low-Dose Mesenchymal Stem Cell Infusion in Lung Transplant Recipients.

David Brett ErasmusNisha DurandFrancisco A AlvarezTathagat NarulaDavid O HodgeAbba C Zubair

Published in: Stem cells translational medicine (2022)

Intravenous infusions of bone marrow-derived MSCs are well tolerated in lung transplant recipients with moderate-to-severe CLAD. Low-dose MSCs appear to slow progression of CLAD in some patients.

Keyphrases

low dose
mesenchymal stem cells
high dose
end stage renal disease
umbilical cord
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
early onset
stem cells
cell therapy
drug induced